Recoflavone

Drug Profile

Recoflavone

Alternative Names: DA-6034

Latest Information Update: 03 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Anti-inflammatories; Antiallergics; Benzopyrans; Eye disorder therapies; Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Calcium channel agonists; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes; Gastritis

Highest Development Phases

  • Phase III Gastritis
  • Phase II Dry eyes
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 03 Sep 2015 Phase-II development is ongoing for Dry eyes
  • 03 Sep 2015 Phase-III development is ongoing for Gastritis
  • 31 Aug 2013 Dong-A ST completes a phase III trial in Gastritis in South Korea (NCT01813812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top